The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study

The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study

To date, the effectiveness of COVID-19 vaccines and booster doses has yet to be evaluated in longitudinal head-to-head studies. This single-center longitudinal study assessed the effectiveness of ChAdOx1 nCoV-19, BNT162b2, and mRNA-1273 vaccines and assessed two BNT162b2 boosters in 1550 participant...

Full description

Bibliographic Details
Main Authors:	Sanaa M. Kamal, Moheyeldeen Mohamed Naghib, Moataz Daadour, Mansour N. Alsuliman, Ziad G. Alanazi, Abdulaziz Abdullah Basalem, Abdulaziz M. Alaskar, Khaled Saed
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Viruses
Subjects:	COVID-19 vaccines booster vaccines doses effectiveness COVID-19-related disease SARS CoV-2 antibody
Online Access:	https://www.mdpi.com/1999-4915/15/2/326

Similar Items

Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine
by: Chalerm Liwsrisakun, et al.
Published: (2022-05-01)

Antibody Detection in Healthcare Workers after Vaccination with Two Doses of the BNT162b2 or ChAdOx1 Vaccine
by: Kyoung Ho Roh, et al.
Published: (2022-09-01)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
by: Passakorn Wanchaijiraboon, et al.
Published: (2023-02-01)

Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
by: Amal Hasan, et al.
Published: (2022-07-01)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
by: Norazida Ab Rahman, et al.
Published: (2023-08-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
by: Simone Barocci, et al.
Published: (2022-03-01)

COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
by: Jung Yeon Heo, et al.
Published: (2022-09-01)

Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis
by: Bianca Maria Wahlen, et al.
Published: (2022-07-01)

Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses
by: Chulyong Park, et al.
Published: (2021-08-01)

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru
by: Stephanie Montero, et al.
Published: (2023-08-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals
by: Roberto Lozano-Rodríguez, et al.
Published: (2023-04-01)

Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals
by: Nuchjira Takheaw, et al.
Published: (2023-04-01)

Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study
by: Chiara Citterio, et al.
Published: (2024-01-01)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
by: Suvimol Niyomnaitham, et al.
Published: (2023-04-01)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
by: Alexandre Vallée, et al.
Published: (2021-08-01)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
by: Meliha Cagla Sonmezer, et al.
Published: (2022-07-01)

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
by: Mohammad Shehab, et al.
Published: (2021-12-01)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
by: Kristi Tsz-Wan Lai, et al.
Published: (2022-04-01)

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study
by: Hakan Demirhindi, et al.
Published: (2022-04-01)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023-01-01)

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
by: Sutima Luangdilok, et al.
Published: (2022-09-01)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
by: Gian Luca Salvagno, et al.
Published: (2022-06-01)

Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study
by: Aziza A. Ajlan, et al.
Published: (2022-10-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
by: José Jesús Broseta, et al.
Published: (2022-03-01)

Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization
by: Ficociello LH, et al.
Published: (2022-11-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
by: Line Dam Heftdal, et al.
Published: (2023-12-01)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
by: Jie Wei, et al.
Published: (2023-02-01)

Willingness and Perceptions Regarding COVID-19 Vaccine Booster Dose in Pakistani Vaccinated Population: A Cross-Sectional Survey
by: Abdul Moeed, et al.
Published: (2022-06-01)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
by: Laura Gianserra, et al.
Published: (2022-08-01)

Subacute Thyroiditis Developing Within 2 Days of Vaccination Against COVID-19 with BNT162b2 mRNA
by: Kenya Ie, et al.
Published: (2023-02-01)

Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine
by: Juan C. Gómez de la Torre, et al.
Published: (2023-04-01)

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
by: Tzu-Chien Lin, et al.
Published: (2023-06-01)

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
by: Hassen Mohammed, et al.
Published: (2023-01-01)

Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells
by: Yuta Yamaguchi, et al.
Published: (2022-11-01)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
by: Somruedee Chatsiricharoenkul, et al.
Published: (2022-10-01)

The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
by: Soonok Sa, et al.
Published: (2022-02-01)